Brief: Guard Therapeutics Closes Phase 2 Clinical Trial

Disruptive Pharma AB (publ)

14/04/2023 10:34

April 14 (Reuters) - Guard Therapeutics International AB
(publ)  GUARD.ST :
    * GUARD THERAPEUTICS CLOSES ITS PHASE 2 CLINICAL TRIAL AKITA
FOLLOWING DMC RECOMMENDATION
    * EXTERNAL AND INDEPENDENT DATA MONITORING COMMITTEE (DMC)
RECOMMENDS TERMINATION OF ONGOING PHASE 2 CLINICAL TRIAL AKITA
    * COMPANY HAS DECIDED TO FOLLOW DMC RECOMMENDATION, WHICH
MEANS
THAT FURTHER PATIENT RECRUITMENT IS DISCONTINUED AND THAT STUDY
IS TERMINATED PREMATURELY BECAUSE PROBABILITY OF ACHIEVING
STUDY'S MAIN OBJECTIVES IS CONSIDERED LOW

Source text for Eikon:  ID:nMFN9yfkWK 
Further company coverage:  GUARD.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))